E 7449

Drug Profile

E 7449

Alternative Names: E-7449

Latest Information Update: 29 Sep 2015

Price : $50

At a glance

  • Originator Eisai Co Ltd
  • Class Antineoplastics
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported B cell lymphoma; Solid tumours

Most Recent Events

  • 24 Sep 2015 No recent reports of development identified - Phase-I/II for Solid tumours in United Kingdom (PO)
  • 24 Sep 2015 No recent reports of development identified - Phase-I/II for B-cell lymphoma in United Kingdom (PO)
  • 17 Oct 2011 Phase-I/II clinical trials in Solid tumours in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top